| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 42.24 | 3605 |
| Intrinsic value (DCF) | 27670.96 | 2427177 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
BioRestorative Therapies, Inc. (NASDAQ: BRTX) is a pioneering biotechnology company specializing in regenerative medicine, leveraging adult stem cell therapies to address unmet medical needs in disc/spine disease and metabolic disorders. The company's flagship program, brtxDisc, features BRTX-100, an autologous mesenchymal stem cell therapy currently in Phase 1 clinical trials for treating painful lumbosacral disc disorders. Additionally, its ThermoStem program targets obesity and metabolic disorders through brown adipose-derived stem cells, currently in preclinical development. With strategic collaborations including Rohto Pharmaceutical, Pfizer, and the University of Pennsylvania, BioRestorative is positioned at the forefront of cell-based therapeutic innovation. Headquartered in Melville, New York, the company focuses on non-surgical, minimally invasive solutions, differentiating itself in the competitive biotech landscape. Investors and stakeholders recognize its potential to disrupt traditional treatment paradigms for chronic conditions.
BioRestorative Therapies presents a high-risk, high-reward investment opportunity given its early-stage clinical programs and focus on regenerative medicine—a rapidly growing sector. While its Phase 1 brtxDisc program shows promise, the company’s financials reflect typical biotech challenges: minimal revenue ($401K in latest reporting), significant net losses (-$8.98M), and heavy reliance on funding to sustain operations (operating cash flow: -$8.23M). The lack of debt is a positive, but its low cash reserves ($547K) raise liquidity concerns. The stock’s low beta (0.36) suggests relative insulation from market volatility, but regulatory hurdles and clinical trial outcomes remain critical risks. Success in advancing BRTX-100 or securing additional partnerships could drive valuation upside.
BioRestorative competes in the niche but expanding regenerative medicine market, where its autologous stem cell approach (BRTX-100) differentiates it from generic pharmaceuticals and surgical interventions. Its focus on non-surgical disc treatment aligns with industry shifts toward minimally invasive therapies, but it faces stiff competition from larger biotechs with deeper pipelines and resources. The ThermoStem program’s targeting of obesity—a $100B+ global market—positions it against metabolic therapy developers, though its preclinical status lags behind rivals. Collaborations with Pfizer and Rohto lend credibility, but the company’s small scale limits R&D bandwidth compared to peers. Key advantages include IP around its curved needle delivery device and autologous cell processing, but scalability and trial success are unproven. Its micro-cap status ($12.5M market cap) makes it vulnerable to dilution or acquisition.